Search hospitals > Washington > Seattle
Kaiser Permanente Washington
Claim this profileSeattle, Washington 98112
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
Conducts research for Lung Cancer
151 reported clinical trials
6 medical researchers
Summary
Kaiser Permanente Washington is a medical facility located in Seattle, Washington. This center is recognized for care of Cancer, Breast Cancer, Recurrence, Adenocarcinoma, Lung Cancer and other specialties. Kaiser Permanente Washington is involved with conducting 151 clinical trials across 391 conditions. There are 6 research doctors associated with this hospital, such as Alison K. Conlin, Michael D. Hogarty, Benjamin B. Bridges, and Joseph E Glass, PhD MSW.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Alison K. ConlinProvidence Portland Medical Center4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
104 reported clinical trials
181 drugs studied
Michael D. HogartyChildren's Hospital of Philadelphia1 year of reported clinical research
Studies Ganglioneuroblastoma
Studies Neuroblastoma
2 reported clinical trials
3 drugs studied
Benjamin B. BridgesProvidence Alaska Medical Center12 years of reported clinical research
Studies Breast Cancer
Studies Fallopian Tube Carcinoma
2 reported clinical trials
8 drugs studied
Joseph E Glass, PhD MSWKaiser Permanente Washington2 years of reported clinical research
Studies Substance Use Disorders
Studies Alcohol Use Disorder
3 reported clinical trials
6 drugs studied
Clinical Trials running at Kaiser Permanente Washington
Non-Small Cell Lung Cancer
Breast Cancer
Lung Cancer
Ovarian Tumors
Ovarian Carcinoma
Testicular Carcinoma
Ovarian Choriocarcinoma
Germ Cell Tumors
Testicular Choriocarcinoma
Testicular Tumor
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Osimertinib
for Non-Small Cell Lung Cancer
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recruiting1 award Phase 242 criteria
Genetic Testing
for Early-Stage Lung Cancer
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Kaiser Permanente Washington?
Kaiser Permanente Washington is a medical facility located in Seattle, Washington. This center is recognized for care of Cancer, Breast Cancer, Recurrence, Adenocarcinoma, Lung Cancer and other specialties. Kaiser Permanente Washington is involved with conducting 151 clinical trials across 391 conditions. There are 6 research doctors associated with this hospital, such as Alison K. Conlin, Michael D. Hogarty, Benjamin B. Bridges, and Joseph E Glass, PhD MSW.